Abstract:4539 Background: The Target of Rapamycin (mTOR) pathway is upregulated in many human cancers, through activation of downstream targets such as AKT and HIF. Pre-clinical data suggests that agents targeting this pathway may be more effective in PTEN null tumors. Studies of agents targeting the mTOR pathway in RCC have shown frequent disease stabilization but relatively few objective responses. The aim of this study was to characterize the mTOR pathway in RCC by immunohistochemistry (IHC), and to determine its utility in selecting patients for agents targeting the mTOR pathway. Methods: An RCC tissue microarray containing specimens for 417 patients was subjected to IHC with antibodies against PTEN, pAKT, pS6, p27, and HIF1 alpha. The original tumors were staged according to the 1997 TNM, graded according to Fuhrman, and histologically subtyped according to the recommendations of the UICC. IHC expression was analyzed according to tumor type, stage, and grade. Pearson correlation analyses were used to determine the relationships between markers. Results: Loss of PTEN was increased in all RCC compared to normal, with the greatest loss occurring in Clear Cell Tumors (24.8%) and tumors having sarcomatoid features (34.4%). pAKT staining frequency was greatest in Collecting Duct (88.9%) followed by Clear Cell (57.5%), suggesting pathways of AKT activation other than PTEN loss. S6 kinase was highly expressed by sarcomatoid (61.1%) and Clear Cell tumors (40.8%) and was expressed more in high grade (73% vs. 31%) and high stage (50% vs 30%) tumors. Expression of HIF1 was highest in Clear Cell, but at only 25% positivity. PTEN expression was correlated with pAKT (p=0.028) and HIF expression (p<0.0001). Conclusions: IHC analysis suggest that not all RCC tumor types are equally amenable to treatment strategies targeting the mTOR pathway, but that a majority of patients have at least one component of the mTOR pathway impacted. Furthermore, the results suggest the mTOR pathway is more significantly altered in high grade tumors and tumors with poor prognostic features. Further evaluation is needed to assess the relationship of IHC results and clinical response, which could result in better patient selection. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Wyeth

Mechanistic Target of Rapamycin Kinase is a Common Convergent Pathway to Renal Neoplasia: A Contemporary Review

TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma

Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated Mtor Pathway in Renal Cell Carcinomas

Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Mechanisms of mTOR inhibitor resistance in cancer therapy

Characterization of the Mtor Pathway in Renal Cell Carcinoma and Its Use in Predicting Patient Selection for Agents Targeting This Pathway

The Genetics of Tuberous Sclerosis Complex and Related mTORopathies: Current Understanding and Future Directions

Targeting Mtor for Cancer Therapy

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity.

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy

Targeting Mtor Network in Colorectal Cancer Therapy

The PI3K/AKT Pathway and Renal Cell Carcinoma.

Wide morphological spectrums of renal neoplasms with TSC/mTOR, NF2, or monoallelic MUTYH germline mutation

mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK

Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy.

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Mtor Signaling Pathway and Cancer